Domainex successful in securing Biomedical Catalyst Feasibility Award
Domainex to Present at a Range of Industry Events in December 2011, including Epigenetics Summit in Munich, including:
This is to recognise its work on the development of a new cancer drug against the novel kinase targets TBK1/IKKe.
Cambridge Business Media Interview (External link)
Domainex Ltd, a biotechnology company providing world-class drug discovery services to support both its own and customer research programmes, has announced plans to significantly expand its medicinal chemistry and biology capabilities in 2011.
Business Weekly Interview (External link)
Domainex Ltd, the leading UK-based drug discovery CRO, has won the 2010 Genesis Life Science Innovation and Enterprise Programme Of The Year Award.
Domainex Ltd announces the appointment of Dr Joanne McCudden as Head of Business Development.
The two-stage funding round will bring in a significant investment from Longbow, The Capital Fund, Bury Fitzwilliam-Lay & Partners LLP, and Takeda Research Investment, Inc. (TRI).